恒瑞医药(01276.HK)：SHR-1139注射液获得药物临床试验批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of SHR-1139 injection, a self-developed biopharmaceutical with no similar drugs approved in the market [1] Group 1: Company Developments - The company’s subsidiary, Guangdong Hengrui Medicine Co., Ltd., has been authorized to conduct clinical trials for SHR-1139 injection [1] - The total research and development investment for the SHR-1139 injection project has reached approximately 100.13 million yuan [1] Group 2: Market Context - Currently, there are no similar drugs approved for market use domestically or internationally, indicating a potential unique market position for SHR-1139 injection [1]